Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

6
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
6
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

5
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
5

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring communication between people living with motor neurone disease and their close persons with healthcare professionals: a longitudinal qualitative United Kingdom study protocol.

BMJ open·2026
Same author

Missed opportunities for Hepatitis C Virus screening and care among persons hospitalized for injection-related infections.

Drug and alcohol dependence·2026
Same author

Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.

The New England journal of medicine·2026
Same author

A qualitative exploration of how people with motor neurone disease who use tracheostomy ventilation understand and experience quality of life.

Disability and rehabilitation·2026
Same author

HEPLISAV-B Breaks Immune Tolerance and Induces HBV Control via CD4 T Cell-Dependent Mechanisms in a Chronic Hepatitis B Mouse Model.

bioRxiv : the preprint server for biology·2026
Same author

Reducing Hospital Readmissions for Injection Drug Use-Related Infections: A Rapid Qualitative Analysis of Health Care Teams' Consultations to Inform Intervention Design.

Journal of addiction medicine·2026
Same journal

Prevalence and associated factors of metabolic dysfunction-associated steatotic liver disease in Taiwan, 2001-2021.

Hepatology international·2026
Same journal

Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study.

Hepatology international·2026
Same journal

APASL clinical practice guidance: the diagnosis and management of patients with Wilson's disease.

Hepatology international·2026
Same journal

Pathological transcriptional retention of Cyp26b1 in perirenal adipose-derived stem cells contributes to MASLD progression.

Hepatology international·2026
Same journal

APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.

Hepatology international·2026
Same journal

Efficacy of radiation therapy plus targeted therapy with or without immunotherapy for lymph node metastases in hepatocellular carcinoma.

Hepatology international·2026
See all related articles

Related Experiment Video

Updated: Mar 19, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

8.0K

Hepatitis C genotype 3 disease.

Sarah Kattakuzhy1, Rachel Levy2, Elana Rosenthal3

  • 1Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, 5415 W, Cedar Lane Suite 203b, Bethesda, MD, 20814, USA. skattakuzhy@ihv.umaryland.edu.

Hepatology International
|June 23, 2016
PubMed
Summary
This summary is machine-generated.

Hepatitis C genotype 3 is difficult to treat, causing liver issues. New direct-acting antivirals show promise for eradicating this infection, though more research is needed.

Keywords:
Genotype-3Hepatitis CTreatment review

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.8K

Related Experiment Videos

Last Updated: Mar 19, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

8.0K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.8K

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C genotype 3 (GT-3) accounts for 30% of global HCV infections, with a high prevalence in South/Southeast Asia.
  • GT-3 infection is linked to increased risks of steatosis, fibrosis, and hepatocellular carcinoma, making it a priority for treatment.
  • Current direct-acting antiviral agents show variable efficacy against GT-3 compared to other genotypes.

Purpose of the Study:

  • To review the epidemiology and natural history of Hepatitis C genotype 3.
  • To summarize findings from Phase II and III clinical trials for GT-3 treatment options.
  • To discuss current and future therapeutic challenges in eradicating GT-3.

Main Methods:

  • Literature review of epidemiological data.
  • Analysis of clinical trial results for direct-acting antivirals in GT-3 patients.
  • Synthesis of current therapeutic landscape and future directions.

Main Results:

  • GT-3 infection presents unique challenges due to its association with significant liver disease progression.
  • Clinical trials are evaluating novel direct-acting antivirals with varying degrees of success in GT-3.
  • Eradication of GT-3 remains a complex therapeutic issue requiring further investigation.

Conclusions:

  • Hepatitis C genotype 3 represents a significant global health burden requiring effective and accessible treatment strategies.
  • Ongoing research and clinical trials are crucial for developing potent therapies against GT-3.
  • Addressing the specific challenges of GT-3 is essential for the overall goal of hepatitis C virus eradication.